**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

----

**Form      10-QSB**

----

**[X]**

**01-06914**

| **Worldwide                Biotech & Pharmaceutical Company**            |
|------------------------------------------------------------------------------|
| (Name                of small business issuer in its                charter) |

| **Delaware**                                                                                              |       | **59-0950777**                                             |
|-----------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------|
| (State                or other jurisdiction of Incorporation)                                             |       | (IRS                Employer Identification Number)        |
|                                                                                                      |       |                                                       |
| **4 Fenghui South              Road,              15th              Floor, A10-11501 **              | ** ** | ** **                                                 |
| **Jie                Zuo Mansion, Xi’an, Shaanxi,****P.R.                China 710075  ** | ** ** | **  ****86-29-88193339**                    |
|  (Address of principal              executive offices)                                          |       |  (Issuer’s              telephone number)  |

----

**PART      I - FINANCIAL INFORMATION**

**Item      1. Financial Statements**

| WORLDWIDE                  BIOTECH & PARMACEUTICAL COMPANY AND SUBSIDIARIES |
|---------------------------------------------------------------------------------|
| CONSOLIDATED                  BALANCE SHEETS                                    |
| June                  30, 2006                                                  |
| (Unaudited)                                                                     |

| ASSETS                                                                                                      |   |       |   |
|-------------------------------------------------------------------------------------------------------------|--------|------------|--------|
|                                                                                                        |   |       |   |
| CURRENT                  ASSETS:                                                                            |   |       |   |
|     Cash                                                                                | $      | 89,381     |   |
|     Marketable                  securities                                              |   | 512,446    |   |
|     Accounts                  receivable, net of allowance for doubtful accounts of     |   | 173,018    |   |
|     Inventories                                                                         |   | 435,654    |   |
|     Prepayments                  and                  other current assets              |   | 144,799    |   |
|                                                                                                        |   |       |   |
|         Total                  Current Assets                       |   | 1,355,298  |   |
|                                                                                                        |   |       |   |
| PROPERTY                  AND EQUIPMENT - Net                                                               |   | 4,724,565  |   |
|                                                                                                        |   |       |   |
| LICENSES,                  net                                                                              |   | 457,750    |   |
|                                                                                                        |   |       |   |
| LAND                  USE RIGHTS, net                                                                       |   | 1,394,471  |   |
|                                                                                                        |   |       |   |
|         Total                  Assets                               | $      | 7,932,084  |   |
|                                                                                                        |   |       |   |
|                                                                                                        |   |       |   |
| LIABILITIES                  AND STOCKHOLDERS' EQUITY                                                       |   |       |   |
|                                                                                                        |   |       |   |
| CURRENT                  LIABILITIES:                                                                       |   |       |   |
|     Loans                  payable                                                      | $      | 1,484,182  |   |
|     Mortgages                  payable                                                  |   | 31,430     |   |
|     Note                  payable - stockholder                                         |   | 425,303    |   |
|     Accounts                  payable                                                   |   | 894,325    |   |
|     Due                  to                  related parties                            |   | 2,032,658  |   |
|     Other                  current liabilities                                          |   | 199,806    |   |
|                                                                                                        |   |       |   |
|         Total                  Current Liabilities                  |   | 5,067,704  |   |
|                                                                                                        |   |       |   |
| MORTGAGES                  PAYABLE, less current portion                                                    |   | 221,599    |   |
|                                                                                                        |   |       |   |
| NOTE                  PAYABLE                                                                               |   | 1,250,891  |   |
|                                                                                                        |   |       |   |
| MINORITY                  INTEREST                                                                          |   | 535,363    |   |
|                                                                                                        |   |       |   |
|         Total                  Liabilities                          |   | 7,075,557  |   |
|                                                                                                        |   |       |   |
| STOCKHOLDERS'                  EQUITY:                                                                      |   |       |   |
|     Common                  stock ($.001 par value; 90,000,000 shares authorized;       |   | 40,358     |   |
|         40,357,502                  shares issued and outstanding)  |   |       |   |
|     Additional                  paid-in capital                                         |   | 10,799,993 |   |
|     Accumulated                  deficit                                                |   | (9,094,289 | )      |
|     Deferred                  compensation                                              |   | (774,000   | )      |
|     Accumulated                  other comprehensive loss:                              |   |       |   |
|     Change                  in unrealized loss on marketable securities                 |   | (160,327   | )      |
|     Foreign                  currency translation gain                                  |   | 44,792     |   |
|                                                                                                        |   |       |   |
|         Total                  Stockholders' Equity                 |   | 856,527    |   |
|                                                                                                        |   |       |   |
|         Total                  Liabilities and Stockholders' Equity | $      | 7,932,084  |   |

| See                  notes to consolidated financial                  statements. |
|-----------------------------------------------------------------------------------|

----

| WORLDWIDE                    BIOTECH & PARMACEUTICAL COMPANY AND SUBSIDIARIES |
|-----------------------------------------------------------------------------------|
| CONSOLIDATED                    BALANCE SHEETS(unaudited)                         |

|                                                                                                                 |   | **For                    The Three Months Ended** |       | **For                    The Six Months Ended** |   |
|----------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|------------|-------------------------------------------------|--------|
|                                                                                                                 |   | **June                    30,**                   |       | **June                    30,**                 |   |
|                                                                                                                 |   | **2006**                                          |       | **2005**                                        |   | **2006** |   | **2005** |   |
| NET                    REVENUES                                                                                      |   | $                                                 | 91,312     |                                            | $      | - |   | $ | 202,633 |   | $ | - |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| COST                    OF GOODS SOLD                                                                                |   |                                              | 78,074     |                                            |   | - |   |   | 184,091 |   |   | - |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| GROSS                    PROFIT                                                                                      |   |                                              | 13,238     |                                            |   | - |   |   | 18,542 |   |   | - |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| OPERATING                    EXPENSES:                                                                               |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|     Selling                    expenses                                                          |   |                                              | 34,493     |                                            |   | - |   |   | 46,864 |   |   | - |   |
|     Research                    and                    development                               |   |                                              | 15,036     |                                            |   | - |   |   | 29,328 |   |   | 55,075 |   |
|     Professional                    fees                                                         |   |                                              | 21,312     |                                            |   | 38,607 |   |   | 101,749 |   |   | 67,468 |   |
|     Stock-based                    compensation                                                  |   |                                              | 249,500    |                                            |   | 1,216,106 |   |   | 599,000 |   |   | 2,475,628 |   |
|     General                    and administrative                                                |   |                                              | 194,012    |                                            |   | 95,594 |   |   | 361,694 |   |   | 168,631 |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|         Total                    Operating Expenses                          |   |                                              | 514,353    |                                            |   | 1,350,307 |   |   | 1,138,635 |   |   | 2,766,802 |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| LOSS                    FROM OPERATIONS                                                                              |   |                                              | (501,115   | )                                               |   | (1,350,307 | ) |   | (1,120,093 | ) |   | (2,766,802 | ) |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| OTHER                    INCOME (EXPENSE):                                                                           |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|     Interest                    income                                                           |   |                                              | 43         |                                            |   | - |   |   | 117 |   |   | 2,809 |   |
|     Interest                    expense                                                          |   |                                              | (62,429    | )                                               |   | (19,672 | ) |   | (141,918 | ) |   | (66,703 | ) |
|     Other                    income (exense)                                                     |   |                                              | (412       | )                                               |   | 43,791 |   |   | 14,672 |   |   | 43,791 |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|         Total                    Other Income (Expense)                      |   |                                              | (62,798    | )                                               |   | 24,119 |   |   | (127,129 | ) |   | (20,103 | ) |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| LOSS                    BEFORE MINORITY INTEREST                                                                     |   |                                              | (563,913   | )                                               |   | (1,326,188 | ) |   | (1,247,222 | ) |   | (2,786,905 | ) |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| MINORITY                    INTEREST                                                                                 |   |                                              | 135,842    |                                            |   | - |   |   | 135,842 |   |   | - |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| NET                    LOSS                                                                                          |   |                                              | (428,071   | )                                               |   | (1,326,188 | ) |   | (1,111,380 | ) |   | (2,786,905 | ) |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| OTHER                    COMPREHENSIVE INCOME                                                                        |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|     Change                    in unrealized loss on marketable securities                        |   |                                              | 242,932    |                                            |   | (90,560 | ) |   | 277,419 |   |   | (90,560 | ) |
|     Foreign                    currency translation gain                                         |   |                                              | 374        |                                            |   | - |   |   | 14,435 |   |   | - |   |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| COMPREHENSIVE                    LOSS                                                                                |   | $                                                 | (184,765   | )                                               | $      | (1,416,748 | ) | $ | (819,526 | ) | $ | (2,877,465 | ) |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
| NET                    LOSS PER COMMON SHARE - BASIC AND DILUTED:                                                    |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|     Net                    loss per common share                                                 |   | $                                                 | (0.01      | )                                               | $      | (0.04 | ) | $ | (0.03 | ) | $ | (0.08 | ) |
|                                                                                                                 |   |                                              |       |                                            |   |   |   |   |   |   |   |   |   |
|     Weighted                    Common                    Shares Outstanding - basic and diluted |   |                                              | 40,357,502 |                                            |   | 37,859,300 |   |   | 40,283,979 |   |   | 36,565,389 |   |

| See                      notes to consolidated financial                      statements. |
|-------------------------------------------------------------------------------------------|

----

| WORLDWIDE                      BIOTECH AND PHARMACEUTICAL COMPANY AND SUBSIDIARIES |
|------------------------------------------------------------------------------------|
| CONSOLIDATED                      STATEMENTS OF CASH FLOWS(unaudited)              |

| CASH                        FLOWS FROM OPERATING ACTIVITIES:                 |   |   |       |   |   |       |   |
|------------------------------------------------------------------------------|--------|--------|------------|--------|--------|------------|--------|
| Net                        loss                                              |   | $      | (1,111,380 | )      | $      | (2,786,905 | )      |
| Adjustments                        to reconcile net loss to net cash used in |   |   |       |   |   |       |   |
| operating                        activities:                            |   |   |       |   |   |       |   |
| Depreciation                        and amortization                    |   |   | 192,820    |   |   | 46,567     |   |
| Stock-based                        compensation                         |   |   | 599,000    |   |   | 2,475,628  |   |
| Minority                        interest                                |   |   | (135,842   | )      |   | -          |   |
| Changes                        in assets and liabilities:                    |   |   |       |   |   |       |   |
| Accounts                        receivable                              |   |   | (29,540    | )      |   | -          |   |
| Inventories                                                             |   |   | (75,042    | )      |   | -          |   |
| Prepayments                        and other current assets             |   |   | 8,927      |   |   | (695,839   | )      |
| Accounts                        payable                                 |   |   | (85,631    | )      |   | 44,230     |   |
| Other                        current liabilities                        |   |   | (10,863    | )      |   | 30,165     |   |
|                                                                         |   |   |       |   |   |       |   |
| NET                        CASH USED IN OPERATING ACTIVITIES                 |   |   | (647,551   | )      |   | (886,154   | )      |
|                                                                         |   |   |       |   |   |       |   |
| CASH                        FLOWS FROM INVESTING ACTIVITIES:                 |   |   |       |   |   |       |   |
| Cash                        used for business acquisitions                   |   |   | (425,303   | )      |   | -          |   |
| Cash                        received from business acquisitions              |   |   | 13,784     |   |   | -          |   |
| Purchase                        of property and equipment                    |   |   | (14,382    | )      |   | (230,797   | )      |
|                                                                         |   |   |       |   |   |       |   |
| NET                        CASH USED IN INVESTING ACTIVITIES                 |   |   | (425,901   | )      |   | (230,797   | )      |
|                                                                         |   |   |       |   |   |       |   |
| CASH                        FLOWS FROM FINANCING ACTIVITIES:                 |   |   |       |   |   |       |   |
| Proceeds                        from loan payable                            |   |   | 600,428    |   |   | -          |   |
| Payments                        on loan payable                              |   |   | (625,446   | )      |   | (60,911    | )      |
| Proceeds                        from note payable - stockholder              |   |   | 425,303    |   |   | -          |   |
| Payments                        on mortgages payable                         |   |   | (17,501    | )      |   | (13,563    | )      |
| Proceeds                        from stockholders/officers                   |   |   | 685,544    |   |   | 363,507    |   |
|                                                                         |   |   |       |   |   |       |   |
| NET                        CASH PROVIDED BY FINANCING ACTIVITIES             |   |   | 1,068,328  |   |   | 289,033    |   |
|                                                                         |   |   |       |   |   |       |   |
| EFFECT                        OF EXCHANGE RATE CHANGES ON CASH               |   |   | (65        | )      |   | -          |   |
|                                                                         |   |   |       |   |   |       |   |
| NET                        DECREASE IN CASH                                  |   |   | (5,189     | )      |   | (827,918   | )      |
|                                                                         |   |   |       |   |   |       |   |
| CASH                        at beginning of period                           |   |   | 94,570     |   |   | 1,047,675  |   |
|                                                                         |   |   |       |   |   |       |   |
| CASH                        at end of period                                 |   | $      | 89,381     |   | $      | 219,757    |   |
|                                                                         |   |   |       |   |   |       |   |
| SUPPLEMENTAL                        DISCLOSURE OF CASH FLOW INFORMATION:     |   |   |       |   |   |       |   |
|  Interest                        paid                                   |   | $      | 139,407    |   | $      | 66,703     |   |

| See                          notes to consolidated financial                          statements. |
|---------------------------------------------------------------------------------------------------|

----

**NOTE      1 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING      POLICIES**

**Basis      of Presentation**

**The      Company**

----

**Revenue      recognition**

----

**NOTE      2 -**
**ACQUISITIONS**

**Pro      Forma Results**

|                                |   | **For                The Three Months Ended June 30, 2005** | ** ** | **For                The Six Months Ended June 30, 2005** |   |
|-------------------------------------|--------|-------------------------------------------------------------|------------|-----------------------------------------------------------|--------|
|                                |   |                                                        |       |                                                      |   |
| Revenues                            |   | $                                                           | 102,689    |                                                      | $      | 214,146 |   |
|                                |   |                                                        |       |                                                      |   |   |   |
| Net                loss             |   | $                                                           | (1,416,925 | )                                                         | $      | (2,904,903 | ) |
|                                |   |                                                        |       |                                                      |   |   |   |
| Basic                loss per share |   | $                                                           | (0.04      | )                                                         | $      | (0.08 | ) |
|                                |   |                                                        |       |                                                      |   |   |   |
|                                |   |                                                        |       |                                                      |   |   |   |

**NOTE      3 - INVENTORIES**

| Raw                materials      |   | $      | 144,752 |   |
|---------------------------------------------|--------|--------|---------|--------|
| Work                in progress   |   |   | 40,282  |   |
| Finished                goods     |   |   | 250,620 |   |
|                                        |   | $      | 435,654 |   |

----

**NOTE      4 - LOANS PAYABLE**

|                                                                                                                                                                                                                                                                                                                                        |   |   |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-----------|
| Loan                payable, unsecured, payable to a financial institution, guaranteed                by an                independent third party, with interest at 7.254% per annum payable                monthly, with principal due October 26, 2006.                                                                                  |   | $      | 875,624   |   |
|                                                                                                                                                                                                                                                                                                                                        |   |   |      |   |
| Loans                payable, to certain employees, with interest at 14.4% per annum.                Such                amounts are due on demand.                                                                                                                                                                                         |   |   | 8,130     |   |
|                                                                                                                                                                                                                                                                                                                                        |   |   |      |   |
| Loan                payable, unsecured, payable to a financial institution, with interest                at                7.02% per annum payable monthly, with principal due May 21, 2007                and                collateralized by substantially all of Ze An’s equipment, buildings and                land use rights. |   |   | 600,428   |   |
|                                                                                                                                                                                                                                                                                                                                        |   |   |      |   |
| Total                                                                                                                                                                                                                                                                                                                                       |   | $      | 1,484,182 |   |

**NOTE      5 - RELATED PARTY TRANSACTIONS**

**Due      to related parties**

----

**Item      2. Management’s Discussion and Analysis or Plan of      Operation**

**Critical      Accounting Policies**

----

**Results      of Operations**

----

**Results      of operations for the six months ended June 30, 2006 as compared to the six      months ended June 30, 2005**

**Revenues**

**Cost      of Sales and Gross Profit**

**Operating      Expenses **

|   | · | For                the six months ended June 30, 2006, we incurred selling expense of                $46,864                compared to $0 for the six months ended June 30, 2005. The increase                was                due to an increased marketing effort of Shaanxi and selling activities                from Hua Yang and Ze An, majority owned subsidiaries the Company                acquired                on January 19, 2006. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | For                the six months ended June 30, 2006, we incurred research and development                expense of $29,328 compared to $55,075 for the six months ended June                30,                2005, a decrease of $25,747 or (46.7%). The decrease was due to regulatory                approval of certain major products of the                Company. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | For                the six months ended June 30, 2006, we incurred professional fees                of                $101,749 as compared to $67,468 for the six months ended June 30,                2005, an                increase of $34,281, or 50.8%. The increase was due to an increase                in                amounts paid to various consultants and professionals related to                our                patents, related legal matters and business acquisitions. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Stock-based                compensation expense decreased to $599,000 for the six months ended                June                30, 2006 from $2,475,628 for the six months ended June 30, 2005.                The                decrease in stock-based compensation expense was attributable to                the                reduction of amortization of deferred compensation. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | For                the six months ended June 30, 2006, general and administrative expenses                were $361,694 as compared to $168,631 for the six months ended June                30,                2005, an increase of $193,063, or approximately 114.5%. In the 2006                period, we incurred additional marketing fees, travel-related expenses                and                other administrative expenses due to the acquisition of two pharmaceutical                companies, Ze An and Hua Yang. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Results      of Operations for the three months ended June 30, 2006 compared to the three      months ended June 30, 2005**

**Revenues**

**Cost      of Sales and Gross Profit**

----

**Operating      Expenses **

|   | · | For                the three months ended June 30, 2006, we incurred selling expense                of                $34,493 compared to $0 for the three months ended June 30, 2005.                The                increase was due to an increased marketing effort of Shaanxi and                selling                activities from Hua Yang and Ze An, majority owned subsidiaries the                Company acquired on January 19,                2006. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | For                the three months ended June 30, 2006, we incurred research and development                expense of $15,036 compared to $0 for the three months ended June                30,                2005, an increase of $15,036. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | For                the three months ended June 30, 2006, we incurred professional fees                of                $21,312 as compared to $38,607 for the three months ended June 30,                2005, a                decrease of $17,295, or 44.8%. The decrease was due to a decrease                in                amounts paid to various consultants and professionals related to                our                patents and related legal matters. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Stock-based                compensation expense decreased to $249,500 for the three months ended                June                30, 2006 from $1,216,106 for the three months ended June 30, 2005.                The                decrease in stock-based compensation expense was attributable to                the                reduction of amortization of deferred compensation. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | For                the three months ended June 30, 2006, general and administrative                expenses                were $194,012 as compared to $95,594 for the three months ended June                30,                2005, an increase of $98,418, or approximately 103.0%. In the second                quarter of 2006, we incurred additional marketing fees, travel-related                expenses and other administrative expenses compared to the same period                in                the prior year due to the acquisition of two pharmaceutical companies,                Ze                An and Hua Yang. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**LIQUIDITY      AND CAPITAL RESOURCES **

----

**Going      Concern**

**Off      Balance Sheet Arrangements **

----

**Impact      of Recently Issued Accounting Pronouncements**

**Item      3. Controls and Procedures**

----

**PART      II**

**Item      1. Legal Proceedings**

**Item      2. Unregistered Sales of Equity Securities and Use of      Proceeds**

**Item      3. Defaults upon Senior Securities**

**Item      4. Submission of Matters to a Vote of Security Holders**

**Item      5. Other Information**

----

**Item      6. Exhibits**

| **Exhibit                No.** | **Description                of Exhibit**                                                             |
|--------------------------------|-------------------------------------------------------------------------------------------------------|
|                           |                                                                                                  |
| 31.1                      | Rule                13a - 14(a)/15d-14(a) Certification of the Chief                Executive Officer |
| 31.2                 | Rule                13a - 14(a)/15d-14(a) Certification of the Chief                Financial Officer |
| 32.1                 | Section                1350 certification                                                             |
| 32.2                 | Section                1350                certification                                              |

----

**SIGNATURES**

|                                          |                                                                                         |                             |
|-----------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------|
|                                          | **Worldwide                Biotech & Pharmaceutical Company**                            |
|                                     |                                                                                    |                        |
| Date:August              1,              2006 | By:                                                                                | /s/ Wenxia              Guo |
|                                          | Wenxia              Guo                                                                      |
|                                          | Chief                Executive Officer, Director(Principal                Executive Officer) |

|                                              |                                                                                                                 |                               |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------|
|                                              |                                                                                                                 |
|                                         |                                                                                                            |                          |
| Date:August                1,                2006 | By:                                                                                                        | /s/ Peiyi                Tian |
|                                              | Peiyi TianVP,                  Treasurer, CFO, Director(Principal                  Financial and Accounting Officer) |

|                                                  |                         |                                  |
|-------------------------------------------------------|------------------------------|---------------------------------------|
|                                                  |                         |
|                                             |                    |                             |
| Date:August                  1,                  2006 | By:                | /s/ JianJun                  Liu |
|                                                  | JianJun                  Liu |
|                                                  | Director                     |

|                                                      |                            |                                     |
|-----------------------------------------------------------|---------------------------------|------------------------------------------|
|                                                      |                            |
|                                                 |                       |                                |
| Date:August                    1,                    2006 | By:                   | /s/ Huimin                    Zhang |
|                                                      | Huimin                    Zhang |
|                                                      | Director                        |

----